Jason Valent

Dr. Jason Valent

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2018 in Amyloid
Verified
Journal Article
Closed access
AIAsad Ikram
Asad Ikram
JDJoseph P. Donnelly
Joseph P. Donnelly
BSBrett W. Sperry
Brett W. Sperry
CSChristy Samaras
Christy Samaras
JVJason Valent
Jason Valent
MHMazen Hanna
Mazen Hanna
Objective: Transthyretin (ATTR) amyloidosis is an under-recognized, progressive disease manifesting as cardiomyopathy and/or polyneuropathy. Diflunisal, a nonsteroidal anti-inflammatory drug (NSAID), has demonstrated transthyretin stabilization in vitro and slowing of polyneuropathy progression in the hereditary ATTR subtype (ATTRm). However, the use of diflunisal has only been described in a small cohort of patients with ATTR cardiac amyloidosis (CA). We hypothesized that selected patients with ATTR-CA, both hereditary and wild-type (ATTRwt), would tolerate diflunisal with limited adverse events. Materials and methods: This is a retrospective, longitudinal study of 23 patients with ATTR-CA (10 ATTRm and 13 ATTRwt) diagnosed at the Cleveland Clinic from May 2007 to August 2017 who were treated with diflunisal. Patients were prescribed diflunisal, fully informed of the risks of side effects. Patient characteristics and subsequent adverse events were recorded. Results: The duration of diflunisal therapy ranged from 1–89 months (median 15 months). Average eGFR at diflunisal initiation was 61.9 ± 15.4 mL/min/m2. Only one patient had a transient rise in Cr of 0.31 mg/dL. There were no clinically significant bleeding events, despite most of the patients being on anticoagulants or antiplatelet agents. Three of 23 patients (13%) withdrew treatment due to drug side effects (erosive gastritis, epigastric pain and decreased appetite). No patients died or were hospitalized for heart failure. Conclusion: Diflunisal was well-tolerated in both the ATTRm- and ATTRwt-CA populations. Withdrawal due to side effects was related to gastrointestinal complaints, but most patients had no adverse events. Diflunisal can be safely used in a selected group of ATTR-CA patients with appropriate clinical, renal and hematologic monitoring.

3 February 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
DBDiana Basali
Diana Basali
RCRajshekhar Chakraborty
Rajshekhar Chakraborty
LRLisa Rybicki
Lisa Rybicki
NRNathaniel Rosko
Nathaniel Rosko
JRJanice Reed
Janice Reed
JVJason Valent
Jason Valent
Summary: The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti‐apoptotic protein BCL‐2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax‐based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non‐haematologic toxicities, most commonly gastrointestinal upset, were observed.

Verified
Journal Article
Open access
PDF file
CLCindy Hsin-Ti Lin
Cindy Hsin-Ti Lin
MTMuhammad Junaid Tariq
Muhammad Junaid Tariq
FUFauzia Ullah
Fauzia Ullah
ASAishwarya Sannareddy
Aishwarya Sannareddy
FKFarhan Khalid
Farhan Khalid
DDDanai Dima
Danai Dima
Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal dysfunction, infection, bone pain, hypercalcemia, and fatigue. Despite numerous recent advancements in the MM treatment paradigm, current therapies demonstrate limited long-term effectiveness and eventual disease relapse remains exceedingly common. Myeloma cells often develop drug resistance through clonal evolution and alterations of cellular signaling pathways. Therefore, continued research of new targets in MM is crucial to circumvent cumulative drug resistance, overcome treatment-limiting toxicities, and improve outcomes in this incurable disease. This article provides a comprehensive overview of the landscape of novel treatments and emerging therapies for MM grouped by molecular target. Molecular targets outlined include BCMA, GPRC5D, FcRH5, CD38, SLAMF7, BCL-2, kinesin spindle protein, protein disulfide isomerase 1, peptidylprolyl isomerase A, Sec61 translocon, and cyclin-dependent kinase 6. Immunomodulatory drugs, NK cell therapy, and proteolysis-targeting chimera are described as well.

5 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DDDanai Dima
Danai Dima
FUFauzia Ullah
Fauzia Ullah
SMSandra Mazzoni
Sandra Mazzoni
LWLouis Williams
Louis Williams
BFBeth M. Faiman
Beth M. Faiman
FAFaiz Anwwer
Faiz Anwwer
Multiple myeloma (MM) is the second most common hematologic malignancy in adults worldwide. Over the past few years, major therapeutic advances have improved progression-free and overall survival, as well as quality of life. Despite this recent progress, MM remains incurable in the vast majority of cases. Patients eventually relapse and become refractory to multiple drug classes, making long-term management challenging. In this review, we will focus on the treatment paradigm of relapsed/refractory MM (RRMM) in the era of advanced therapies emphasizing the available novel modalities that have recently been incorporated into routine practice, such as chimeric antigen receptor T-cell therapy, bispecific antibodies, and other promising approaches. We will also discuss major factors that influence the selection of appropriate drug combinations or cellular therapies, such as relapse characteristics, and other disease and patient related parameters. Our goal is to provide insight into the currently available and experimental therapies for RRMM in an effort to guide the therapeutic decision-making process.

21 January 2019 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
RCRajshekhar Chakraborty
Rajshekhar Chakraborty
HLHien D. Liu
Hien D. Liu
LRLisa Rybicki
Lisa Rybicki
JTJacqulyn Tomer
Jacqulyn Tomer
JKJack Khouri
Jack Khouri
JVJason Valent
Jason Valent

1 January 2021 in Seminars in Hematology
Verified
Journal Article
Closed access
JKJack Khouri
Jack Khouri
BFBeth M Faiman
Beth M Faiman
DGDale Grabowski
Dale Grabowski
RMReda Z. Mahfouz
Reda Z. Mahfouz
SKShahper N Khan
Shahper N Khan
FRFrederic J Reu
Frederic J Reu